2 active not recruiting, 2 not yet recruiting, 1 completed, 1 unknown. 3 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Not yet recruiting 2, Completed 1 |
| Not applicable | 1 | Unknown 1 |
Follow Platinum-Doublet Chemotherapy: new trials by email Literature Review of Platinum-Doublet Chemotherapy trials Research Report on Platinum-Doublet Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-30 |
| SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer SHR-1701 combined with platinum-doublet chemotherapy induction therapy, SHR-1701 consolidation therapy, Platinum-doublet chemotherapy - NSCLC Stage III, SHR-1701 | Phase 2 | Not yet recruiting | Fudan University | 84 | 2026-07-01 | 2026-06-02 |
| Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy - Resectable Non-Small-Cell Lung Cancer | Not applicable | Unknown | Xuanwu Hospital, Beijing | 40 | 2024-10-15 | 2024-09-23 |
| Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants REGN2810, Platinum-doublet chemotherapy - Advanced Non-small Cell Lung Cancer | Active not recruiting | Regeneron Pharmaceuticals | 1000 | 2024-02-21 | 2026-09-10 | |
| A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors BMS-986408, Nivolumab, Ipilimumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 68 | 2022-08-02 | 2026-08-13 |
| Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy - Advanced Malignancies | Phase 1 | Active not recruiting | Regeneron Pharmaceuticals | 146 | 2017-06-21 | 2026-02-12 |
Carcinoma, Non-Small-Cell Lung (3) · Neoplasms (1)
Regeneron Pharmaceuticals (2) · Bristol-Myers Squibb (1) · Fudan University (1) · VA Office of Research and Development (1) · Xuanwu Hospital, Beijing (1)
United States (3) · Canada (1) · China (1) · France (1) · Japan (1) · Spain (1) · Switzerland (1)
Charles J Nock, MD (1) · Yi Zhang (1)